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Frequent tumor relapse in hepatocellular carcinoma (HCC) has been commonly attributed to the 
failure to completely eradicate cancer stem cells (CSCs) in the tumor residues by conventional 
treatments. We have previously reported that the tumor growth of HCC is fuelled, at least in part, 
by a small subset of CSCs marked by the CD133 surface phenotype. Our present study aims 1) to 
delineate the molecular mechanism by which CD133+ liver CSCs mediate HCC tumor formation 
and progression; and 2) to develop a novel diagnostic / prognostic biomarker and targeted therapy 
for HCC detection and treatment. RNA-Seq profiling was employed to compare the gene 
expression profiles between sorted CD133+ and CD133- subsets isolated from HCC cell lines 
Huh7 and PLC8024. Annexin A3 (ANXA3) was identified as the most significantly up-regulated 
secretory protein in the CD133+ subset. Validation in additional HCC cell lines and clinical 
samples likewise showed ANXA3 to be preferentially expressed in the CD133+ subset. Up-
regulation of ANXA3 in both endogenous and secretory forms was tightly associated with 
advanced tumor stages. In addition, quantification of serum ANXA3 provides a novel biomarker 
with high specificity and sensitivity for HCC diagnosis. Functional studies involving lentiviral-
based knockdown and overexpression approaches found ANXA3 to regulate cancer and stem 
cell-like properties including tumor initiation, migration, invasion, angiogenesis, self-renewal and 
resistance to chemotherapy and apoptosis. Subsequent gene expression profiling by cDNA 
microarray found ANXA3 to be functionally involved in driving CD133+ CSCs via a deregulated 
JNK/AP-1 pathway. In light of the functional significance and clinical relevance of ANXA3 in 
HCC, we subsequently developed a novel neutralizing monoclonal antibody specific against 
ANXA3 and tested for its application as a therapeutic treatment against HCC. In vitro functional 
studies showed that ANXA3 neutralizing antibody treatment dramatically reduced cell 
proliferation, sphere formation, migration, invasion, angiogenesis, and sensitized cells to 
apoptosis and cisplatin treatment in vitro. This observation was further confirmed in vivo where 
neutralizing antibody treatment attenuated tumor growth, concomitant with a reduced CD133+ 
subset in the residual xenografts. Mechanistically, treatment of HCC cells with ANXA3 
neutralizing antibody in vitro and in vivo, similarly led to a suppressed JNK pathway. Taken 
together, ANXA3 confers both cancer and stem cell-like properties in CD133+ liver CSCs via 
JNK pathway. ANXA3 neutralizing antibody possesses therapeutic effect in HCC by eliminating 
CD133+ liver CSCs. We believe that ANXA3 could serve as a potential therapeutic target to 
attain complete eradication of HCC. 
